This retrospective cohort study of patients with different neoplasms undergoing thermal ablation, embolization, or selective internal radiotherapy (SIRT) and anti-PD-1/PD-L1 agents (monotherapy with pembrolizumab, nivolumab and atezolizumab, and ipilimumab plus nivolumab) ≤ 90 days before or ≤30 days after the interventional procedure, showed no unmanageable or unexpected toxicity [40]. This evidence concerns the gene CD274 and neoplasm.